New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 26, 2017 – The FDA announced the approval of Cycle Pharmaceuticals’ Nityr (nitisinone) tablets, for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Download PDF
Return to publications
